Zoetis stock
ZTSNYSEZoetis Inc., HealthcareISIN US98978V1035
75Score 75 out of 100, Strong
Price and trend
53 / 100
Price history
−31% in one yearThe chart shows daily closes over 14 years, adjusted for stock splits and without dividends. Click into the chart to set a price alert at that price.
Below the 200-day line: the price is 10% below it.
Since December 2024 the 50-day line has been below the 200-day line; the trend has turned down.
Normal: the price is neither overheated nor sold off (RSI 51).
The price is 37% below its 52-week high. Largest decline in 14 years: 72% (December 2021 to October 2026).
Chart figures for advanced users
- SMA 50$76.00
- Average price of the last 50 trading days, shows the short-term trend.
- SMA 200$91.87
- Average price of the last 200 trading days, shows the long-term trend.
- RSI (14)51
- Relative strength over the last 14 days on a scale from 0 to 100. Above 70 the price counts as overheated, below 30 as sharply fallen.
- MACDbelow the signal line
- Compares a fast and a slow price average. Above its signal line momentum is rising, below it momentum is fading.
- Support$69.10
- The lowest closing price of the last twelve months.
- Resistance$131.10
- The highest closing price of the last twelve months.
Snapshot
Computed from the data by fixed rules, no AI
- Zoetis Inc. belongs to the Drug Manufacturers (Specialty & Generic) industry (United States) and, with a market value of $33.55B, is number 10 of 78 companies in its industry on MEQIRI.
- In fiscal 2025 it reported revenue of $9.47B (up 2.3% year on year) and earnings of $2.67B (up 7.5%).
- For fiscal 2026, analysts expect on average revenue of $9.27B (down 2.1%) and adjusted earnings per share of $6.21 (down 3.2%).
Show more
- MEQIRI Score 75 out of 100 (Strong): rank 76 of 714 in Healthcare, median 53.
- The P/E is 13.7 (Drug Manufacturers (Specialty & Generic) median 19.3, own median of recent years 35.7).
- Our model puts fair value at $131.68, with the price 37% below it.
In plain words
The numbers on this page in plain words, written by an AI
Strengths
- High return on capitalReturn on invested capital 28.6% in fiscal 2025, Drug Manufacturers (Specialty & Generic) median 7%.Profitability 96
- Below fair valuePrice 37% below the fair value of $131.68.Valuation 81
- High marginNet margin 26.1% over the last 12 months, Drug Manufacturers (Specialty & Generic) median 8.6%.Profitability 96
Weaknesses
- High debtDebt 2.8 times equity (latest quarter), Drug Manufacturers (Specialty & Generic) median 0.49.Stability 61
- Share price fell sharplyDown 31% over the last 12 months.Momentum 52
Its standout strengths are profitability and capital allocation.
Daily figure as of 12 Nov 2026
How the score is calculatedScore overview
Fundamentals are strong, with stable profits and strong cash generation.
Score history
The full history of up to 20 years comes with MEQIRI Pro.
See plansCrash risk medium
How well MEQIRI warnsIn the middle among stocks ranked 101 to 1,000.
From 2016 to 2025, 13 in 100 such stocks fell 30% or more within a year, against a group average of 15 in 100.
What drives the risk
- price far below its 52-week high
- high price swings
What lowers it
- solid fundamentals
- price not overheated over the past year
Valuation
Valuation signal
Significantly undervaluedIn our model the price counts as cheap below $101.29 and expensive above $188.11 (uncertainty medium, based on the price swings of the past year).
The two parts of the fair value come to $146.54 (cash-flow model) and $116.81 (industry comparison), and the gap between them shows how uncertain the estimate is. The price is below both.
Calculated with a cost of equity of 8.8%. At 9.8% the fair value would be $118.69, at 7.8% it would be $151.22.
Valuation metrics
Half from the cash-flow model, half from earnings times the industry P/E (19.3).
Calculate with your own assumptionsCompany performance
This shows several years of history with an automatic assessment.
Revenue
In the twelve months to 30 Sep 2026, revenue rose 1.2% on the twelve months before. Revenue has grown solidly since 2009, at about 8% per year.
Margins
- Gross margin
- Operating margin
- Net margin
In fiscal 2025: gross 70%, operating 38%, net 28%.
Debt & balance sheet
latest quarterMeaningfully leveraged, but the interest bill is comfortably covered.
Earnings
- Next earnings
- 11 Feb 2027in 91 days
- Last reported
- 5 Nov 2026EPS reported $1.75 (expected $1.51)above expectations
Analyst estimates
Earnings estimates have barely changed since 15 Oct 2026.
- Earnings per share
- $6.21+0.1%
- Revenue
- $9.27B+0.1%
- Earnings per share
- $6.34−1.1%
- Revenue
- $9.34B−0.6%
MEQIRI has stored the estimates since 15 Oct 2026. Until 30 days are available, the card shows the change since that day. Mean estimate according to Financial Modeling Prep. No price target and no recommendation.
Company outlook lowered
Share price after the results: −2.3%Guidance lowered: organic operational revenue down 3% to 1%, adjusted net income $2.57 billion to $2.62 billion (down 9% to 5%), adjusted EPS $6.15 to $6.25, due to pressure in companion animal.
“We now expect adjusted net income to be in the range of $2.57 billion to $2.62 billion, representing a decline of 9% to 5% year-over-year on an organic operational basis, reflective of the revenue headwinds noted above, partially offset by the cost and productivity actions we are executing across the organization.”The outlook is not part of the score and not a recommendation to buy or sell.
From the earnings call on 6 Aug 2026 (fiscal Q2 2026), read by AI.
Insiders
Open-market purchases and sales by executives, board members and major holders
2 insiders bought on the open market in the last 6 months, $653,094 in total.
Source: Form 4 filings with the US Securities and Exchange Commission. Grants, option exercises, gifts and tax withholdings are hidden. Not a recommendation to buy.
What happened at Zoetis
The key events of the last six months from our own data. A click takes you to the matching card.
Sector comparison
714 rated companies in Healthcare
- This company
- 75
- Sector median
- 53
Categories against the sector median
The median is the middle value: half of the companies in the sector lie above it, half below. Categories with too few comparable companies are left out.
Competitors in Drug Manufacturers (Specialty & Generic)
The next larger and next smaller companies by market value
- Jiangsu Hengrui Medicine600276.SS $46.11B70
- Sandoz GroupSDZ.SW $44.42B66
- Jiangsu Hengrui Pharmaceuticals1276.HK $42.51B67
- HaleonHLN $40.35B61
- Divi's LaboratoriesDIVISLAB.NS $32.21B75
- Hansoh Pharmaceutical Group3692.HK $26.55B79
- ViatrisVTRS $24.14B55
- Torrent PharmaceuticalsTORNTPHARM.NS $19.33B63
ETFs that hold Zoetis
Held by 136 ETFs on Xetra. Shown per index: the ETF with the largest weight.
| ETF | Weight | Cost | Fund size |
|---|---|---|---|
| VanEck Morningstar US ESG Wide Moat UCITS ETFGMVM | 1.99% | 0.49% | €368.7M |
| iShares MSCI World Health Care Sector Advanced UCITS ETFCBUF | 0.78% | 0.18% | €837.43M |
| Invesco Global Buyback Achievers UCITS ETFBBCK | 0.56% | 0.39% | €188.08M |
Show 5 more
| Xtrackers MSCI USA Health Care UCITS ETF 1DXUHC | 0.54% | 0.12% | €1.34B |
| UBS Factor MSCI USA Quality Screened UCITS ETF hEUR accUBUX | 0.54% | 0.28% | €1.14B |
| iShares S&P 500 Health Care Sector UCITS ETFQDVG | 0.54% | 0.15% | €3.27B |
| UBS Factor MSCI USA Prime Value Screened UCITS ETF hEUR accUBUW | 0.52% | 0.28% | €127.84M |
| iShares MSCI USA Quality Dividend Advanced UCITS ETFQDVD | 0.52% | 0.35% | €777.04M |
Holdings as reported by the funds via FMP, excluding swap ETFs (their holdings are only collateral).
Data status and sources
- Score
- Daily value of 12 Nov 2026, recalculated nightly
- Price
- Closing price of 11 Nov 2026
- Latest annual report
- Fiscal year 2025, period end 31 Dec 2025
- Source
- Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.
Mandatory disclosures for this rating
- ; time horizon around 12 months
- Rated Strong, published since 7 Nov 2026 (in the score history since 2 Oct 2026)
- Valuation signal Undervalued since 7 Nov 2026
- End-of-day prices, metrics cached for up to 24 hours
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.